drugset / Trial / NCT00993031

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

NCT00993031

RandomizedParallel-groupOpen-labelPrevention

Summary

This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell counts at high risk of malaria. The study is designed to test the hypothesis that pregnant women receiving a PI-based ART regimen will have lower risk of placental malaria compared to pregnant women receiving a non-PI based ART regimen. The primary study endpoint of the study is placental malaria. This study also enrolls the infants of these women at the time of delivery.

Timeline

Start
2009-12-15
Primary completion
2013-07
Completion
2013-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 600 mg
Subject Lopinavir/ritonavir Unknown 50 mg
Subject Lopinavir/ritonavir Unknown 200 mg
Background Lamivudine Other / unclassified 150 mg
Background Zidovudine Small molecule 300 mg